Exploration of Targeted Anti-tumor Therapy

Open Access Original Article

Cola rostrata K. Schum. constituents induce cytotoxicity through reactive oxygen species generation and mitochondrial membrane depolarisation

Babatunde E. Ajayi ... Amos A. Fatokun

Published: December 28, 2023 Explor Target Antitumor Ther. 2023;4:1328–1344

DOI: https://doi.org/10.37349/etat.2023.00200

This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents

Full Text PDF

2632 27 3

Open Access Review

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes

Chaoqun Li ... Jieer Ying

Published: December 28, 2023 Explor Target Antitumor Ther 2023;4:1310–1327

DOI: https://doi.org/10.37349/etat.2023.00199

This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer

Full Text PDF

2967 16 1

Open Access Perspective

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?

Sabah Alaklabi ... Shipra Gandhi

Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1301–1309

DOI: https://doi.org/10.37349/etat.2023.00198

This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer

Full Text PDF

2905 28 0

Open Access Review

Current implications and challenges of artificial intelligence technologies in therapeutic intervention of colorectal cancer

Kriti Das ... Chakresh Kumar Jain

Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1286–1300

DOI: https://doi.org/10.37349/etat.2023.00197

This article belongs to the special issue Artificial Intelligence for Precision Oncology

Full Text PDF

3341 42 5

Open Access Review

Post-translational modulation of cell signalling through protein succinylation

Katharina F. Kubatzky ... Dayoung Yu

Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1260–1285

DOI: https://doi.org/10.37349/etat.2023.00196

This article belongs to the special issue Posttranslational Modifications in Health and Disease

Full Text PDF

7017 67 10

Open Access Review

Telehealth in breast cancer following the coronavirus disease 2019 pandemic

Jean Zeghondy ... Barbara Pistilli

Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1249–1259

DOI: https://doi.org/10.37349/etat.2023.00195

This article belongs to the special issue COVID-19 and Cancer

Full Text PDF

2294 17 0

Open Access Review

Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy

Mansi Joshi ... Abhijit De

Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1227–1248

DOI: https://doi.org/10.37349/etat.2023.00194

This article belongs to the special issue Posttranslational Modifications in Health and Disease

Full Text PDF

4091 70 5

Open Access Original Article

Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status

Ali JN Duabil ... George DD Jones

Published: December 21, 2023 Explor Target Antitumor Ther. 2023;4:1210–1226

DOI: https://doi.org/10.37349/etat.2023.00193

Full Text PDF

2811 28 0

Open Access Original Article

Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer

Vignesh Sivaganesh, Bela Peethambaran

Published: December 20, 2023 Explor Target Antitumor Ther. 2023;4:1188–1209

DOI: https://doi.org/10.37349/etat.2023.00192

Full Text PDF

2861 29 4

Open Access Case Report

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

Sviatoslav Chekhun ... Maria Saigí

Published: December 13, 2023 Explor Target Antitumor Ther. 2023;4:1182–1187

DOI: https://doi.org/10.37349/etat.2023.00191

Full Text PDF

2510 20 0

Open Access Review

Targeting cancer stem cell plasticity in triple-negative breast cancer

Zhengwang Guo, Shuyan Han

Published: December 11, 2023 Explor Target Antitumor Ther. 2023;4:1165–1181

DOI: https://doi.org/10.37349/etat.2023.00190

This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer

Full Text PDF

3817 51 5

Open Access Case Report

Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer

Alexey V. Emshanov ... Evgeny N. Imyanitov

Published: December 06, 2023 Explor Target Antitumor Ther. 2023;4:1157–1164

DOI: https://doi.org/10.37349/etat.2023.00189

Full Text PDF

2202 24 1

Open Access Original Article

Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy

Witida Laopajon ... Watchara Kasinrerk

Published: December 06, 2023 Explor Target Antitumor Ther. 2023;4:1145–1156

DOI: https://doi.org/10.37349/etat.2023.00188

This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer

Full Text PDF

2752 30 0

Open Access Meta-Analysis

Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis

Marco Filetti ... Gennaro Daniele

Published: December 01, 2023 Explor Target Antitumor Ther. 2023;4:1136–1144

DOI: https://doi.org/10.37349/etat.2023.00187

Full Text PDF

2592 56 1